Clinical Trial Update: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating retatrutide (LY3437943) for obesity or overweight with knee osteoarthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Osteoarthritis of the Knee

Drugs mentioned

• Retatrutide (retatrutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 3 | Status: COMPLETED